TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population

  • Chowdhury, Miraj Kobad (Department of Genetic Engineering and Biotechnology, University of Dhaka) ;
  • Moniruzzaman, Md (Department of Genetic Engineering and Biotechnology, University of Dhaka) ;
  • Al Emran, Abdullah (Department of Genetic Engineering and Biotechnology, University of Dhaka) ;
  • Mostafa, Mohammad Golam (Department of Histopathology, National Institute of Cancer Research and Hospital) ;
  • Kuddus, Ruhul H (Department of Genetic Engineering and Biotechnology, University of Dhaka) ;
  • Uddin, M Aftab (Department of Genetic Engineering and Biotechnology, University of Dhaka)
  • Published : 2015.04.29


Objective: To assess associations between codon 72 polymorphisms (Pro or B and Arg or b alleles) of the TP53 gene and lung cancer risk among Bangladeshis. Materials and Methods: The distribution of the BB, Bb, and bb genotypes and the frequencies of the B and b alleles were determined by PCR-RFLP method using DNA extracted from leucocytes of 50 confirmed lung cancer patients and 50 age-matched controls and the data were analysed. Results: The ratio of BB, Bb, and bb genotypes were in Hardy-Weinberg equilibrium except for the male patients (${\chi}2=4.6$). The B allele is overrepresented among all patients (OR=2.0, p=0.02) and the female patients (OR=4.1, $p{\leq}0.01$) compared to the controls. The BB/bb ratio was also higher among the patients (OR=3.0, p=0.03). The relative risk of cancer for having BB over bb genotype was 1.8 (p=0.04) but no effect was observed for the Bb genotype. The B allele was overrepresented among patients with adenocarcinomas (OR=2.4, $p{\leq}0.01$) and squamous cell carcinomas (OR=2.7, $p{\leq}0.01$) over the controls but the difference was not significant for those with small cell lung carcinomas (OR=1.1, p=0.66). The B allele was overrepresented among patients age 50 or younger (OR=2.7, $p{\leq}0.01$), but not for older patients (OR=1.7, p=0.07), and among smokers compared to the controls (OR=1.8-10.0, $p{\leq}0.01-0.03$). However, no correlation between increasing pack-years and lung cancer was observed. Conclusions: The Pro/Pro (BB) genotype and the B allele are risk factors for lung cancer among Bangladeshis, particularly for people under age 50, women and smokers.


Lung cancer;TP53 gene;codon 72 polymorphism;PCR-RFLP analysis;Bangladeshis


  1. American Cancer Society (2014). What are the risk factors for small cell lung cancer? (accessed, June 2014).
  2. Akhtar PS, Masud ZM, Alam MT et al (2011). Profile of lung cancer: a one-year report. JOM, 12, 115-9.
  3. Alqumber MA, Akhter N, Haque S, et al (2014). Evaluating the Association between p53 Codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis. PLoS One, 9, 94874.
  4. Ara S, Lee PS, Hansen MF, et al (1990). Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res, 18, 4961.
  5. Bellini MF, Cadamuro AC, Succi M, et al (2012). Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol, 2012, 891961.
  6. Birgander R, Sjalander A, Rannug A, et al (1995). P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis, 16, 2233-6.
  7. Bland JM, Altman AJ (2000). The odds ratio. BMJ, 320, 1468.
  8. Cancer Registry Report (2009). National institute of cancer research and hospital and worldhealth organization country office for Bangladesh, Dhaka. in June 2014).
  9. Cancer Research UK (2014). info/cancerstats/types/lung/incidence/uk-lungcancer-incidence-statistics#geog (accessed in June 2014).
  10. Cancerquest (2014). Lung Cancer: Risk factors. risks.html?gclid=CjgKEAjw286dBRDmwbLi8KP71GQSJAAOk4sjPzX0i18l- vh7OkpKuZ86TUJrF9Q-QtO--2NYvPjjMfD_BwE (accessed in June 2014).
  11. Devi KP, Sivamaruti B, Kiruthiga PV, et al (2010). Study of p53 codon 72 polymorphism and codon 249 mutations in SouthernIndia in relation to age, alcoholdrinking and smoking habits. human and experimental toxicology. Hum Exp Toxicol, 29, 451-8.
  12. Dianat SS, Margreiter M, Eckersberger E, et al (2009). Gene polymorphisms and prostate cancer: the evidence. BJU Int, 104, 1560-72.
  13. Fan R, Wu MT, Miller D, et al (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 9, 1037-42.
  14. Ferlay, J. Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  15. Hoe KK, Verma CS, Lane DP (2014). Drugging the p53 pathway:understanding the route to clinical efficacy. Nat Rev Drug Discov, 13, 217-36.
  16. IARC (International agency for research of cancer) (2014). (accessed June 2014).
  17. Jain N, Shing V, Hedau S, et al (2005). Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest, 128, 3999-4007.
  18. Jin X, Wu X, Roth JA, et al (1995). Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 16, 2205-228.
  19. Kawajiri K, Nakachi K, Imai K et al (1993). Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis, 14, 1085-9.
  20. Latil AG, Azzouzi R, Cancel GS, et al (2001). Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 92, 1130-7.<1130::AID-CNCR1430>3.0.CO;2-B
  21. Lu Y, Liu Y, Zeng J, et al (2014). Association of p53 codon 72 polymorphism with prostate cancer: an update metaanalysis. Tumour Biol, 35, 3997-4005.
  22. Luo J, Duggan DJ, Chen Y, et al (2001). Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res, 61, 4683- 8.
  23. Matlashewski G, Pim D, Banks L, et al (1987). Alternative splicing of human p53 transcripts. Oncogene Res, 1, 77-85.
  24. Naccarati A, Polakova V, Pardini B, et al (2011). Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis, 27, 211-8.
  25. Oros KK, Arcand SL, Bayani J, et al (2013). Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genet, 206, 103-15.
  26. Patnala R, Clements J, Batra J (2013). Candidate gene association studies: a comprehensive guide to useful in silico tools. BMC Genet, 14, 39.
  27. Perez-Perez G, Bosques-Padilla FJ, Crosatti ML, et al (2005). Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol, 40, 56-60.
  28. Pierce LM, Sivaraman L, Chang W, et al (2000). Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev, 9, 1199-204.
  29. Prakash K, Pirozzi G, Elashoff M, et al (2002). Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Nat Acad Sci USA, 99, 7598-603.
  30. Qiao Q, Hu W. (2013). The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung, 191, 369-77.
  31. Sheshkin DJ (2004). Handbook of parametric and nonparametric Statistical Procedures. Chapman and Hall/CRC, Boca Raton, FL.
  32. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
  33. Venot C, Maratrat M, Dureuil C, et al (1998). The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J, 17, 4668-79.
  34. von Mering C, Krause R, Snel B, et al (2002). Comparative assessment of large-scale data sets of protein-protein interactions. Nature, 417, 399-403.
  35. Wang S, Lan X, Tan S, Wang S, et al (2013). P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour Biol, 34, 2511-20.
  36. Wang YC, Chen CY, Chen SK, et al (1999). p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res, 5, 129-34.
  37. WHO (World Health Organization). (2004). (accessed June 2014).
  38. WorldHealthRanking (2014). (accessed June 2014).
  39. Yamashita T, Yaginuma Y, Saitoh Y, et al (2014). Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogensis, 20, 1733-6.
  40. Zhao L, Zhao X, Wu X, et al (2013). Association of p53 Arg72Pro polymorphism with esophageal cancer: a metaanalysis based on 14 case-control studies. Genet Test Mol Biomarkers, 17, 721-6.

Cited by

  1. Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer vol.67, pp.4, 2016,
  2. TP53 Codon 72 Genetic Polymorphism, rs1042522, Modifies the Association Between Tobacco Smoking and Breast Cancer Risk vol.19, pp.10, 2017,